Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Aug 17;6(1):305.
doi: 10.1038/s41392-021-00721-1.

"Armed for the future Coronavirus pandemic": a promising use of the multimeric SARS-CoV-2 receptor binding domain nanoparticle as a new Pan-Coronavirus vaccine

Manoj Kumar #  1 , Souhaila Al Khodor  2
Affiliations
Comment

"Armed for the future Coronavirus pandemic": a promising use of the multimeric SARS-CoV-2 receptor binding domain nanoparticle as a new Pan-Coronavirus vaccine

Manoj Kumar et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Schematic representation of the key steps followed to develop and evaluate the SARS-scNP vaccine. The RBD-scNP vaccine elicits extremely high titers of neutralizing antibodies (IgG) against SARS-CoV-2 virus, its emerging variants and other related beta-CoVs including BatCoV-WIV-1, and BatCoV-SHC014. RBD harbors conserved epitopes, including the DH1047 epitope within beta-CoV spikes. Receptor binding domain (RBD); angiotensin-converting enzyme-2 (ACE-2); RBD-sortase A conjugated nanoparticle (RBD-scNP); immunoglobulin G (IgG); severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); coronaviruses (CoVs)
See this image and copyright information in PMC

Comment on

  • Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.
    Saunders KO, Lee E, Parks R, Martinez DR, Li D, Chen H, Edwards RJ, Gobeil S, Barr M, Mansouri K, Alam SM, Sutherland LL, Cai F, Sanzone AM, Berry M, Manne K, Bock KW, Minai M, Nagata BM, Kapingidza AB, Azoitei M, Tse LV, Scobey TD, Spreng RL, Rountree RW, DeMarco CT, Denny TN, Woods CW, Petzold EW, Tang J, Oguin TH 3rd, Sempowski GD, Gagne M, Douek DC, Tomai MA, Fox CB, Seder R, Wiehe K, Weissman D, Pardi N, Golding H, Khurana S, Acharya P, Andersen H, Lewis MG, Moore IN, Montefiori DC, Baric RS, Haynes BF. Saunders KO, et al. Nature. 2021 Jun;594(7864):553-559. doi: 10.1038/s41586-021-03594-0. Epub 2021 May 10. Nature. 2021. PMID: 33971664 Free PMC article.

References

    1. Saunders KO, et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021 doi: 10.1038/s41586-021-03594-0. - DOI - PMC - PubMed
    1. Kumar M, Al Khodor S. Pathophysiology and treatment strategies for COVID-19. J. Transl. Med. 2020;18:353. doi: 10.1186/s12967-020-02520-8. - DOI - PMC - PubMed
    1. Pinto D, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290–295. doi: 10.1038/s41586-020-2349-y. - DOI - PubMed
    1. Menachery VD, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015;21:1508–1513. doi: 10.1038/nm.3985. - DOI - PMC - PubMed
    1. Planas D, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 2021;27:917–924. doi: 10.1038/s41591-021-01318-5. - DOI - PubMed

Publication types

Substances